<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263314</url>
  </required_header>
  <id_info>
    <org_study_id>8266-003</org_study_id>
    <secondary_id>MK-8266-003</secondary_id>
    <nct_id>NCT01263314</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)</brief_title>
  <official_title>A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8266 in Elderly Subjects With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study. The hypothesis for this study
      is that single oral doses of MK-8266 selected for this study are sufficiently safe and well
      tolerated by elderly male and elderly female participants with hypertension to permit
      continued clinical investigation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two panels, each consisting of eight participants (8 elderly males with mild to moderate
      hypertension in Panel A and 8 elderly females with mild to moderate hypertension in Panel B)
      will be randomized to receive either MK-8266 or matching placebo in a 3:1 ratio. Participants
      will receive single doses of MK-8266 or matching placebo in three treatment periods (Periods
      1 through 3). In both Panel A and Panel B, doses will escalate in a rising, fixed sequence.
      In Period 1 (0.3 mg), Period 2 (0.6 mg), and Period 3 (0.7 mg and then 0.3 mg 10 hours later)
      once daily doses of MK-8266 or matching placebo will be administered.

      All participants will receive at least 2 doses of MK-8266. Participants completing placebo
      treatment in Period 1 will flow to the MK-8266 arm in the next period, with 2 participants
      from the MK-8266 arm receiving placebo in the next period.

      Blood samples will be obtained pre-dose and at selected time points up to 48 hours post-dose
      for determination of MK-8266 plasma concentrations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2010</start_date>
  <completion_date type="Actual">March 1, 2011</completion_date>
  <primary_completion_date type="Actual">February 1, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Up to 48 days</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Hematology Values Reported as an AE</measure>
    <time_frame>Up to 48 days</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory hematology value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory hematology value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Chemistry Values Reported as an AE</measure>
    <time_frame>Up to 48 days</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory chemistry value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory chemistry value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Urinalysis Values Reported as an AE</measure>
    <time_frame>Up to 37 days</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory urinalysis value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory urinalysis value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline and 0 to 8 hours postdose</time_frame>
    <description>Participants rested for at least 10 minutes prior to having vital sign measurements obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Heart Rate</measure>
    <time_frame>Baseline and 0 to 8 hours postdose</time_frame>
    <description>Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Heart rate measurements were obtained in the semirecumbent position and 3 sets of measurements were obtained approximately 1 minute apart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiograms (ECG) Reported as an AE</measure>
    <time_frame>Up to 48 days</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. An abnormal ECG value was any AE reported under the System Organ Classes of Investigations or Cardiac that was related to an abnormal ECG value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</measure>
    <time_frame>Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. (AUC[0-inf]) is a measure of the mean concentration levels of drug in the plasma after the dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)</measure>
    <time_frame>Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)</measure>
    <time_frame>Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Nominal instead of actual times are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MK-8266 PK Parameter Apparent Half-Life (t1/2)</measure>
    <time_frame>Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Results are presented for the Harmonic Mean Â± Pseudo standard deviation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time Weighted Average Systolic Blood Pressure (SBP) Evaluated Over 8 Hours Post Dose (TWA[0-8hrs]) Following a Single Oral Dose of MK-8266.</measure>
    <time_frame>Up to 8 hours post dose in each dosing period (Up to 8 hours)</time_frame>
    <description>Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Single dose effects on central SBP were estimated as a time-weighted average over the 8-hour post single dose observation period.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Panel A MK-8266 0.3 mg (Elderly Males with Mild/Mod. HTN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 single dose 0.3 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel A MK-8266 0.6 mg (Elderly Males with Mild/Mod. HTN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 single dose 0.6 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel A MK-8266 0.7/0.3 mg (Elderly Males with Mild/Mod. HTN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel A Placebo to MK-8266 (Elderly Males with Mild/Mod. HTN)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to MK-8266 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B MK-8266 0.3 mg (Elderly Females with Mild/Mod. HTN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 single dose 0.3 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B MK-8266 0.6 mg (Elderly Females with Mild/Mod. HTN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 single dose 0.6 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B MK-8266 0.7/0.3 mg (Elderly Fem. with Mild/Mod. HTN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B Placebo to MK-8266 (Elderly Fem. with Mild/Mod. HTN)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to MK-8266 single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8266</intervention_name>
    <description>Oral capsules, 0.1 mg potency</description>
    <arm_group_label>Panel A MK-8266 0.3 mg (Elderly Males with Mild/Mod. HTN)</arm_group_label>
    <arm_group_label>Panel A MK-8266 0.6 mg (Elderly Males with Mild/Mod. HTN)</arm_group_label>
    <arm_group_label>Panel A MK-8266 0.7/0.3 mg (Elderly Males with Mild/Mod. HTN)</arm_group_label>
    <arm_group_label>Panel B MK-8266 0.3 mg (Elderly Females with Mild/Mod. HTN)</arm_group_label>
    <arm_group_label>Panel B MK-8266 0.6 mg (Elderly Females with Mild/Mod. HTN)</arm_group_label>
    <arm_group_label>Panel B MK-8266 0.7/0.3 mg (Elderly Fem. with Mild/Mod. HTN)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo capsules to match MK-8266 capsules</description>
    <arm_group_label>Panel A Placebo to MK-8266 (Elderly Males with Mild/Mod. HTN)</arm_group_label>
    <arm_group_label>Panel B Placebo to MK-8266 (Elderly Fem. with Mild/Mod. HTN)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Participants are male or non-childbearing female.

          -  Participant with essential hypertension (HTN), Grade 1 or 2 (as per European Society
             of Hypertension [ESH]) or isolated mild to moderate systolic HTN. High normal systolic
             BP â¥130 mmHg will be also allowed. Blood pressures to be confirmed on at least three
             occasions pre-study. The possibility of secondary causes of HTN should be assessed.
             Participants who are being treated for HTN with drugs (including beta blocking
             medications) may be able to participate if the drug doses can be reduced or
             discontinued, at the discretion of the investigator.

          -  Participants with a Body Mass Index (BMI) â¤35 kg/m^2 at the screening visit.

          -  Participants judged to be generally in good health based on medical history, physical
             examination, vital sign measurements (with the exception of HTN), and laboratory
             safety tests performed at the screening visit.

          -  Participant has no clinically significant abnormality (confirmed by the investigator
             in consultation with the Merck Clinical Monitor) on electrocardiogram (ECG) or Holter
             Monitor Evaluation performed at the screening visit and/or prior to administration of
             the initial dose of study drug.

          -  Participants must have a platelet count â¥150,000 cu/mL at the screening and pre-study
             visit.

          -  Participants, at screening, will have a positive Augmentation Index.

          -  Participant has been a nonsmoker and/or has not used nicotine or nicotine-containing
             products for at least 6 months; participants who have discontinued smoking or the use
             of nicotine/nicotine containing products for at least 3 months may be enrolled at the
             discretion of the investigator.

          -  Participant is willing to comply with the study restrictions.

          -  Participant has a negative test for hidden blood in the stool at screening.

        Exclusion criteria:

          -  Participants who have had situational depression may be enrolled in the study at the
             discretion of the investigator.

          -  Participant has an estimated creatinine clearance of â¤60 mL/min based on the
             Cockcroft-Gault equation.

          -  Participant has a history of stroke, chronic seizures, or major neurological disorder.

          -  Participant has a history of clinically significant endocrine, gastrointestinal,
             cardiovascular (with the exception of HTN), hematological, hepatic, immunological,
             renal, respiratory, or genitourinary abnormalities or diseases. Participants with a
             history of uncomplicated kidney stones or childhood asthma may be enrolled in the
             study at the discretion of the investigator.

          -  Patient demonstrates low blood pressure at screening and Pre-dose Day 1 while going
             from a semi-recumbent to standing position.

          -  Participant has a functional disability that can interfere with rising from a
             semi-recumbent position to the standing position.

          -  Participant has any personal or family history of a bleeding or a clotting disorder.

          -  Participant has a history of frequent nosebleeds.

          -  Participant has a history of cancer with the exceptions of: adequately treated
             non-melanoma skin carcinoma or carcinoma in situ of the cervix; other malignancies
             which have been successfully treated &gt;10 years prior to the screening visit, for which
             in the judgment of both the investigator and treating physician, appropriate follow-up
             has revealed no evidence of recurrence from the time of treatment through the time of
             the screening visit; or, participants, who, in the opinion of the study investigator,
             are highly unlikely to sustain a recurrence for the duration of the study.

          -  Participant has a history of clinically significant cardiac disease including, but not
             limited to hemodynamically relevant heart valve disease (if there would be any
             uncertainty about the diagnosis, confirmation with an echocardiography within 3 months
             of screening is required), or evidence of secondary cardiac damage.

          -  Participant is categorized as a class II or greater functional classification for
             heart failure according to the New York Heart Association (NYHA).

          -  Participant is unable to refrain from or anticipates the use of any medication,
             including prescription and non-prescription drugs or herbal remedies (such as St.
             John's Wort [Hypericum perforatum]) beginning approximately 2 weeks (or 5 half-lives)
             prior to administration of the initial dose of study drug, throughout the study until
             the post-study visit. Certain medication use may be permitted after consultation with
             the Merck clinical monitor.

          -  Participant currently and regularly uses aspirin (including low dose) and cannot be
             discontinued from it from 2 weeks prior to study start or has used aspirin within 2
             weeks prior to study start (and anticipates using it during the course of the study);
             this applies also to any pain relievers and cold or sinus remedies that have aspirin
             in them, and the use of anti-platelet drugs, such as clopidogrel or dipyridamole.
             Chronic use of certain non-steroidal anti-inflammatory drugs (NSAIDs) such as â¥500 mg
             of naproxen twice a day must be also avoided beginning at least 2 weeks prior the
             study and until the post-study visit.

          -  Participant anticipates using sildenafil (ViagraÂ®), tadalafil (CialisÂ®), or Vardenafil
             (LevitraÂ®).

          -  Participant uses or anticipates using organic nitrate preparations (for example,
             nitroglycerin, isosorbide mononitrate, isosorbide dinitrate or pentaerythritol) during
             the course of the study.

          -  Participant consumes excessive amounts of alcohol, defined as greater than 3 glasses
             of alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10
             ounces], wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day.
             Participants that consume 4 glasses of alcoholic beverages per day may be enrolled at
             the discretion of the investigator.

          -  Participant consumes excessive amounts, defined as greater than 6 servings (1 serving
             is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other
             caffeinated beverages per day.

          -  Participant has had major surgery, donated or lost 1 unit of blood (approximately 500
             mL) or participated in another investigational study within 4 weeks prior to the
             screening visit. The 4-week window will be derived from the date of the last study
             procedure (i.e., post-study, AE follow-up, etc.) in the previous study to the
             screening visit of the current study.

          -  Participant has a history of significant multiple and/or severe allergies (including
             latex allergy), or has had an anaphylactic reaction or significant intolerability to
             prescription or non-prescription drugs or food.

          -  Participant is currently a regular user of illicit drugs or has a history of
             drug/alcohol abuse within approximately 1 year of the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>November 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2010</study_first_posted>
  <results_first_submitted>March 19, 2018</results_first_submitted>
  <results_first_submitted_qc>March 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2018</results_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All participants will receive at least 2 doses of MK-8266. Participants completing placebo treatment in Period 1 will flow to the MK-8266 arm in the next period, with 2 participants from the MK-8266 arm receiving placebo in the next period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 1</title>
          <description>Period 1: MK-8266 0.3 mg; Period 2: MK-8266 0.6 mg; and Period 3: placebo.</description>
        </group>
        <group group_id="P2">
          <title>Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 2</title>
          <description>Period 1: MK-8266 0.3 mg; Period 2: MK-8266 0.6 mg; and Period 3: MK-8266 0.7 mg and then 0.3 mg after 10 hours.</description>
        </group>
        <group group_id="P3">
          <title>Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 3</title>
          <description>Period 1: MK-8266 0.3 mg; Period 2: placebo; and Period 3: MK-8266 0.7 mg and then 0.3 mg after 10 hours.</description>
        </group>
        <group group_id="P4">
          <title>Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 4</title>
          <description>Period 1: placebo; Period 2: MK-8266 0.6 mg; and Period 3: MK-8266 0.7 mg and then 0.3 mg after 10 hours.</description>
        </group>
        <group group_id="P5">
          <title>Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 1</title>
          <description>Period 1: MK-8266 0.3 mg; Period 2: placebo; and Period 3: MK-8266 0.7 mg and then 0.3 mg after 10 hours.</description>
        </group>
        <group group_id="P6">
          <title>Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 2</title>
          <description>Period 1: MK-8266 0.3 mg; Period 2: MK-8266 0.6 mg; and Period 3: placebo.</description>
        </group>
        <group group_id="P7">
          <title>Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 3</title>
          <description>Period 1: MK-8266 0.3 mg; Period 2: MK-8266 0.6 mg; and Period 3: MK-8266 0.7 mg and then 0.3 mg after 10 hours.</description>
        </group>
        <group group_id="P8">
          <title>Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 4</title>
          <description>Period 1: placebo; Period 2: MK-8266 0.6 mg; and Period 3: MK-8266 0.7 mg and then 0.3 mg after 10 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics for all participants receiving study treatment. Participants are grouped according to either Panel A or Panel B (i.e. males or females with mild/moderate hypertension).</population>
      <group_list>
        <group group_id="B1">
          <title>Panel A (Elderly Males, Mild/Moderate Hypertension)</title>
          <description>MK-8266 (0.3 mg, 0.6 mg, or 0.7 mg and then 0.3 mg after 10 hours) or placebo</description>
        </group>
        <group group_id="B2">
          <title>Panel B (Elderly Females, Mild/Moderate Hypertension)</title>
          <description>MK-8266 (0.3 mg, 0.6 mg, or 0.7 mg and then 0.3 mg after 10 hours) or placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" spread="2.8"/>
                    <measurement group_id="B2" value="68.9" spread="2.8"/>
                    <measurement group_id="B3" value="68.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to 48 days</time_frame>
        <population>All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg
Hypertension (HTN)</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O4">
            <title>Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
          <group group_id="O5">
            <title>Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O8">
            <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>All participants who received at least one dose of the investigational drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Laboratory Hematology Values Reported as an AE</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory hematology value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory hematology value.</description>
        <time_frame>Up to 48 days</time_frame>
        <population>All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O4">
            <title>Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
          <group group_id="O5">
            <title>Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O8">
            <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Laboratory Hematology Values Reported as an AE</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory hematology value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory hematology value.</description>
          <population>All participants who received at least one dose of the investigational drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Laboratory Chemistry Values Reported as an AE</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory chemistry value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory chemistry value.</description>
        <time_frame>Up to 48 days</time_frame>
        <population>All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O4">
            <title>Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
          <group group_id="O5">
            <title>Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O8">
            <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Laboratory Chemistry Values Reported as an AE</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory chemistry value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory chemistry value.</description>
          <population>All participants who received at least one dose of the investigational drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Laboratory Urinalysis Values Reported as an AE</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory urinalysis value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory urinalysis value.</description>
        <time_frame>Up to 37 days</time_frame>
        <population>All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O4">
            <title>Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
          <group group_id="O5">
            <title>Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O8">
            <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Laboratory Urinalysis Values Reported as an AE</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory urinalysis value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory urinalysis value.</description>
          <population>All participants who received at least one dose of the investigational drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP)</title>
        <description>Participants rested for at least 10 minutes prior to having vital sign measurements obtained.</description>
        <time_frame>Baseline and 0 to 8 hours postdose</time_frame>
        <population>All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Mod. HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Mod. HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.7 /0.3 (Elderly Males With Mild/Mod. HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O4">
            <title>Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN)</title>
            <description>Placebo to MK- 8266 single dose</description>
          </group>
          <group group_id="O5">
            <title>Panel B MK-8266 0.3 mg (Elderly Females With Mild/Mod. HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O8">
            <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP)</title>
          <description>Participants rested for at least 10 minutes prior to having vital sign measurements obtained.</description>
          <population>All participants who received at least one dose of the investigational drug.</population>
          <units>Millimeters of mercury</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.3" spread="8.87"/>
                    <measurement group_id="O2" value="137.2" spread="19.09"/>
                    <measurement group_id="O3" value="134.0" spread="12.96"/>
                    <measurement group_id="O4" value="132.7" spread="10.93"/>
                    <measurement group_id="O5" value="141.7" spread="13.38"/>
                    <measurement group_id="O6" value="139.5" spread="11.10"/>
                    <measurement group_id="O7" value="137.7" spread="7.76"/>
                    <measurement group_id="O8" value="142.0" spread="18.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="3.85"/>
                    <measurement group_id="O2" value="-0.79" spread="7.44"/>
                    <measurement group_id="O3" value="-1.13" spread="4.13"/>
                    <measurement group_id="O4" value="0.54" spread="4.83"/>
                    <measurement group_id="O5" value="-0.33" spread="10.01"/>
                    <measurement group_id="O6" value="-4.16" spread="10.25"/>
                    <measurement group_id="O7" value="-2.28" spread="5.87"/>
                    <measurement group_id="O8" value="5.91" spread="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3551</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.01</ci_lower_limit>
            <ci_upper_limit>4.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3474</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.08</ci_lower_limit>
            <ci_upper_limit>4.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3105</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.42</ci_lower_limit>
            <ci_upper_limit>4.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1346</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.8</ci_lower_limit>
            <ci_upper_limit>3.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0416</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.6</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0762</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.7</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Heart Rate</title>
        <description>Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Heart rate measurements were obtained in the semirecumbent position and 3 sets of measurements were obtained approximately 1 minute apart.</description>
        <time_frame>Baseline and 0 to 8 hours postdose</time_frame>
        <population>All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Mod. HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Mod. HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.7 /0.3 (Elderly Males With Mild/Mod. HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O4">
            <title>Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN)</title>
            <description>Placebo to MK- 8266 single dose</description>
          </group>
          <group group_id="O5">
            <title>Panel B MK-8266 0.3 mg (Elderly Females With Mild/Mod. HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O8">
            <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate</title>
          <description>Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Heart rate measurements were obtained in the semirecumbent position and 3 sets of measurements were obtained approximately 1 minute apart.</description>
          <population>All participants who received at least one dose of the investigational drug.</population>
          <units>Beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.83" spread="9.24"/>
                    <measurement group_id="O2" value="67.83" spread="10.53"/>
                    <measurement group_id="O3" value="58.33" spread="5.50"/>
                    <measurement group_id="O4" value="69.00" spread="8.37"/>
                    <measurement group_id="O5" value="65.33" spread="5.32"/>
                    <measurement group_id="O6" value="65.00" spread="5.97"/>
                    <measurement group_id="O7" value="61.33" spread="4.23"/>
                    <measurement group_id="O8" value="63.83" spread="5.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="6.12"/>
                    <measurement group_id="O2" value="4.23" spread="4.78"/>
                    <measurement group_id="O3" value="7.90" spread="4.89"/>
                    <measurement group_id="O4" value="0.11" spread="7.85"/>
                    <measurement group_id="O5" value="2.40" spread="2.37"/>
                    <measurement group_id="O6" value="5.51" spread="3.27"/>
                    <measurement group_id="O7" value="6.65" spread="3.33"/>
                    <measurement group_id="O8" value="1.25" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.418</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.47</ci_lower_limit>
            <ci_upper_limit>4.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0434</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>8.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.79</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.85</ci_lower_limit>
            <ci_upper_limit>11.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2223</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.42</ci_lower_limit>
            <ci_upper_limit>3.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0056</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>6.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.83</ci_lower_limit>
            <ci_upper_limit>7.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Electrocardiograms (ECG) Reported as an AE</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. An abnormal ECG value was any AE reported under the System Organ Classes of Investigations or Cardiac that was related to an abnormal ECG value.</description>
        <time_frame>Up to 48 days</time_frame>
        <population>All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O4">
            <title>Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
          <group group_id="O5">
            <title>Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O8">
            <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiograms (ECG) Reported as an AE</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. An abnormal ECG value was any AE reported under the System Organ Classes of Investigations or Cardiac that was related to an abnormal ECG value.</description>
          <population>All participants who received at least one dose of the investigational drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. (AUC[0-inf]) is a measure of the mean concentration levels of drug in the plasma after the dose.</description>
        <time_frame>Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.</time_frame>
        <population>The subset of participants who comply with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model. AUC[0-inf] was not estimated for participants receiving placebo and for MK-8266 doses below 0.6 mg due to the lack of measureable concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O4">
            <title>Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
          <group group_id="O5">
            <title>Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O8">
            <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
        </group_list>
        <measure>
          <title>MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. (AUC[0-inf]) is a measure of the mean concentration levels of drug in the plasma after the dose.</description>
          <population>The subset of participants who comply with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model. AUC[0-inf] was not estimated for participants receiving placebo and for MK-8266 doses below 0.6 mg due to the lack of measureable concentrations.</population>
          <units>nMâ¢hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="208" spread="81.5"/>
                    <measurement group_id="O3" value="314" spread="108"/>
                    <measurement group_id="O6" value="247" spread="66.8"/>
                    <measurement group_id="O7" value="449" spread="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR (Elderly female/Elderly male)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
            <estimate_desc>GMR = geometric mean ratio</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.</description>
        <time_frame>Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.</time_frame>
        <population>The subset of participants who comply with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Cmax was not estimated for participants receiving placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O4">
            <title>Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
          <group group_id="O5">
            <title>Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O8">
            <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
        </group_list>
        <measure>
          <title>MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.</description>
          <population>The subset of participants who comply with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Cmax was not estimated for participants receiving placebo.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.76" spread="2.25"/>
                    <measurement group_id="O2" value="14.1" spread="3.45"/>
                    <measurement group_id="O3" value="16.2" spread="4.13"/>
                    <measurement group_id="O5" value="7.84" spread="1.80"/>
                    <measurement group_id="O6" value="17.8" spread="2.52"/>
                    <measurement group_id="O7" value="19.5" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR (Elderly female/Elderly male)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR (Elderly female/Elderly male)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR (Elderly female/Elderly male)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Nominal instead of actual times are presented.</description>
        <time_frame>Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.</time_frame>
        <population>The subset of participants who comply with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Tmax was not estimated for participants receiving placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O4">
            <title>Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
          <group group_id="O5">
            <title>Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O8">
            <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
        </group_list>
        <measure>
          <title>MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Nominal instead of actual times are presented.</description>
          <population>The subset of participants who comply with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model. Tmax was not estimated for participants receiving placebo.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.5" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.5" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="2.0" upper_limit="3.0"/>
                    <measurement group_id="O5" value="4.0" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O6" value="3.5" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O7" value="4.0" lower_limit="3.0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-8266 PK Parameter Apparent Half-Life (t1/2)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Results are presented for the Harmonic Mean Â± Pseudo standard deviation.</description>
        <time_frame>Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.</time_frame>
        <population>The subset of participants who comply with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model. t1/2 was not estimated for participants receiving placebo and for MK-8266 doses below 0.6 mg due to the lack of measureable concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O4">
            <title>Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
          <group group_id="O5">
            <title>Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O8">
            <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
        </group_list>
        <measure>
          <title>MK-8266 PK Parameter Apparent Half-Life (t1/2)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Results are presented for the Harmonic Mean Â± Pseudo standard deviation.</description>
          <population>The subset of participants who comply with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model. t1/2 was not estimated for participants receiving placebo and for MK-8266 doses below 0.6 mg due to the lack of measureable concentrations.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="12.7" spread="4.8"/>
                    <measurement group_id="O3" value="14.3" spread="3.8"/>
                    <measurement group_id="O6" value="13.6" spread="4.5"/>
                    <measurement group_id="O7" value="15.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time Weighted Average Systolic Blood Pressure (SBP) Evaluated Over 8 Hours Post Dose (TWA[0-8hrs]) Following a Single Oral Dose of MK-8266.</title>
        <description>Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Single dose effects on central SBP were estimated as a time-weighted average over the 8-hour post single dose observation period.</description>
        <time_frame>Up to 8 hours post dose in each dosing period (Up to 8 hours)</time_frame>
        <population>The analysis population was all participants who received at least 1 dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O4">
            <title>Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
          <group group_id="O5">
            <title>Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.3 mg</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
            <description>MK-8266 single dose 0.6 mg</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
            <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
          </group>
          <group group_id="O8">
            <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
            <description>Placebo to MK-8266 single dose</description>
          </group>
        </group_list>
        <measure>
          <title>The Time Weighted Average Systolic Blood Pressure (SBP) Evaluated Over 8 Hours Post Dose (TWA[0-8hrs]) Following a Single Oral Dose of MK-8266.</title>
          <description>Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Single dose effects on central SBP were estimated as a time-weighted average over the 8-hour post single dose observation period.</description>
          <population>The analysis population was all participants who received at least 1 dose of the investigational drug.</population>
          <units>millimeters of mercury</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.4" spread="11.73"/>
                    <measurement group_id="O2" value="134.2" spread="12.96"/>
                    <measurement group_id="O3" value="132.7" spread="12.34"/>
                    <measurement group_id="O4" value="136.8" spread="8.61"/>
                    <measurement group_id="O5" value="142.4" spread="13.19"/>
                    <measurement group_id="O6" value="135.0" spread="8.22"/>
                    <measurement group_id="O7" value="136.0" spread="6.82"/>
                    <measurement group_id="O8" value="146.6" spread="12.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0253</p_value>
            <method>ANOVA</method>
            <param_type>MK-8266 0.3 mg vs. placebo</param_type>
            <param_value>9.58</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>17.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2856</p_value>
            <method>ANOVA</method>
            <param_type>MK-8266 0.6 mg vs. placebo</param_type>
            <param_value>-2.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.5</ci_lower_limit>
            <ci_upper_limit>5.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1895</p_value>
            <method>ANOVA</method>
            <param_type>MK-8266 0.7 mg/ 0.3 mg vs. placebo</param_type>
            <param_value>-4.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.9</ci_lower_limit>
            <ci_upper_limit>3.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1157</p_value>
            <method>ANOVA</method>
            <param_type>MK-8266 0.3 mg vs. placebo</param_type>
            <param_value>-4.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>ANOVA</method>
            <param_type>MK-8266 0.6 mg vs. placebo</param_type>
            <param_value>-11.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.5</ci_lower_limit>
            <ci_upper_limit>-5.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>ANOVA</method>
            <param_type>MK-8266 0.7 mg/ 0.3 mg vs. placebo</param_type>
            <param_value>-10.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.5</ci_lower_limit>
            <ci_upper_limit>-4.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 48 days</time_frame>
      <desc>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
The analysis population included all participants who received at least one dose of the investigational drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)</title>
          <description>MK-8266 single dose 0.3 mg</description>
        </group>
        <group group_id="E2">
          <title>Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)</title>
          <description>MK-8266 single dose 0.6 mg</description>
        </group>
        <group group_id="E3">
          <title>Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)</title>
          <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
        </group>
        <group group_id="E4">
          <title>Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)</title>
          <description>Placebo to MK-8266 single dose</description>
        </group>
        <group group_id="E5">
          <title>Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)</title>
          <description>MK-8266 single dose 0.3 mg</description>
        </group>
        <group group_id="E6">
          <title>Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)</title>
          <description>MK-8266 single dose 0.6 mg</description>
        </group>
        <group group_id="E7">
          <title>Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)</title>
          <description>MK-8266 0.7 mg and then 0.3 mg after 10 hours</description>
        </group>
        <group group_id="E8">
          <title>Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)</title>
          <description>Placebo to MK-8266 single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="5" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

